- Home
- BIIB vs ROL Comparison
BIIB vs ROL Comparison
Compare BIIB & ROL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ROL
- Stock Information
- Founded
- BIIB 1978
- ROL 1948
- Country
- BIIB United States
- ROL United States
- Employees
- BIIB N/A
- ROL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ROL Diversified Commercial Services
- Sector
- BIIB Health Care
- ROL Finance
- Exchange
- BIIB Nasdaq
- ROL Nasdaq
- Market Cap
- BIIB 25.1B
- ROL 23.9B
- IPO Year
- BIIB 1991
- ROL N/A
- Fundamental
- Price
- BIIB $157.46
- ROL $49.00
- Analyst Decision
- BIIB Buy
- ROL Buy
- Analyst Count
- BIIB 27
- ROL 6
- Target Price
- BIIB $252.20
- ROL $49.83
- AVG Volume (30 Days)
- BIIB 1.5M
- ROL 1.5M
- Earning Date
- BIIB 10-30-2024
- ROL 10-23-2024
- Dividend Yield
- BIIB N/A
- ROL 1.35%
- EPS Growth
- BIIB 10.05
- ROL 16.84
- EPS
- BIIB 11.06
- ROL 0.97
- Revenue
- BIIB $9,607,500,000.00
- ROL $3,310,625,000.00
- Revenue This Year
- BIIB N/A
- ROL $10.99
- Revenue Next Year
- BIIB N/A
- ROL $8.33
- P/E Ratio
- BIIB $14.23
- ROL $50.43
- Revenue Growth
- BIIB N/A
- ROL 11.07
- 52 Week Low
- BIIB $153.62
- ROL $40.41
- 52 Week High
- BIIB $268.30
- ROL $52.16
- Technical
- Relative Strength Index (RSI)
- BIIB 34.89
- ROL 45.10
- Support Level
- BIIB $158.44
- ROL $48.38
- Resistance Level
- BIIB $162.62
- ROL $49.77
- Average True Range (ATR)
- BIIB 3.52
- ROL 0.82
- MACD
- BIIB 0.66
- ROL -0.20
- Stochastic Oscillator
- BIIB 32.53
- ROL 16.85
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ROL Rollins Inc.
Rollins is a global leader in route-based pest-control services, with operations spanning North, Central and South America, Europe, the Middle East and Africa and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, market leader in the US, where it boasts near national coverage, and in Canada. Residential pest and termite prevention dominates the services provided by Rollins, owing to the group's ongoing focus on US and Canadian markets.